| Literature DB >> 36226051 |
Yong-Gang He1, Wen Huang1, Qian Ren1, Jing Li1, Feng-Xia Yang1, Chang-Lin Deng1, Li-Qi Li2, Xue-Hui Peng1, Yi-Chen Tang1, Lu Zheng1, Xiao-Bing Huang1, Yu-Ming Li1.
Abstract
Background: Radical resection remains the most effective treatment for hilar cholangiocarcinoma (HCCA). However, due to the complex anatomy of the hilar region, the tumor is prone to invade portal vein and hepatic arteries, making the surgical treatment of HCCA particularly difficult. Successful laparoscopic radical resection of HCCA(IIIA, IIIB) requires excellent surgical skills and rich experience. Furthermore, the safety and effectiveness of this operation are still controversial. Aim: To retrospectively analyze and compare the efficacy and safety of laparoscopic and open surgery for patients with HCCA.Entities:
Keywords: R0 resection; laparoscopic hilar cholangiocarcinoma; open hilar cholangiocarcinoma; propensity score matching; retrospective study
Year: 2022 PMID: 36226051 PMCID: PMC9549331 DOI: 10.3389/fonc.2022.1004974
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Flow chart of patient enrollment.
Figure 2Procedure of laparoscopic hilar cholangiocrinoma 1. (A) three-dimensional (3D) imaging of the tumor (red arrow); (B) Trocar placement during laparoscopic radical resection for HCCA. The chief operator stands on the right side of the patient, inserting 5-mm and 12-mm trocars into the right abdomen; the first assistant stands on the patient’s left side, placing 5-mm and 12-mm trocars above the umbilicus and on the left abdomen; and the camera-holder stands between the two legs of the patient(yellow arrow). (C) sever the lower end of the common bile duct at the upper border of the pancreas; (D) transect the right hepatic artery(yellow arrow); (E) dissect the lymph nodes in the hilar region(yellow arrow); (F) transect the right hepatic duct(yellow arrow); (G) identify the left branch of portal vein and portal vein (yellow arrow); (H) identify the right branch of portal vein (yellow arrow). CBD, Common bile duct; RHA, Right hepatic artery; RHD, Right hepatic duct; LPV, Left branch of portal vein; PV, Portal vein; RPV, Right branch of portal vein.
Figure 3Procedure of laparoscopic hilar cholangiocrinoma 2. (A–C) resection and reconstruction of left branch of portal vein; (D) liver parenchyma transection-priority approach for liver resection; (E) transection of right hepatic vein using a cutter/staple; (F–H) hepatobliary duct-jejunum anastomosis (placement of T tube). LPV, Left branch of portal vein; PV, Portal vein; LHD,left hepatic duct.
Demographic and baseline characteristics in the OS and LS groups.
| Variables | OS group (n = 32) | LS group (n = 16) |
|
|---|---|---|---|
| Age [median (q1-q3), years] | 62.5(52.25-67) | 64(54-66) | 0.991 |
| BMI[mean ± SD,kg/m2] | 22.7 ± 2.71 | 23.54 ± 2.45 | 0.300 |
| Gender, n (%) | 0.683 | ||
| Female | 16 (50) | 9 (56.25) | |
| Male | 16 (50) | 7 (43.75) | |
| ASA score, n (%) | 0.781 | ||
| 1 | 20 (62.5) | 9 (56.25) | |
| 2 | 9(28.12) | 6 (37.5) | |
| 3 | 3 (9.38) | 1 (6.25) | |
| Underlying diseases (heart disease, lung disease, diabetes, etc.), n (%) | 0.911* | ||
| None | 23 (71.88) | 11 (68.75) | |
| Yes | 9 (28.12) | 5 (31.25) | |
| Smoking, n(%) | 7 (21.88) | 2 (12.5) | 0.695* |
| Drinking, n (%) | 5 (15.63) | 2 (12.5) | 0.885* |
| PTBD, n (%) | 21 (65.63) | 12(75) | 0.509* |
| History of abdominal surgery, n (%) | 5 (15.63) | 4 (21.05) | 0.885* |
| Biochemistry | |||
| CA19-9[median (q1-q3), U/ml] | 150.66(16.09-800) | 135.74(50.94-587.83) | 0.775 |
| CEA[median (q1-q3), ng/ml] | 4.13(2.2-6.26) | 2.45(1.94-3.95) | 0.094 |
| CA125[median (q1-q3), U/ml] | 18.95(11.8-28.5) | 15.9(10.5-26.2) | 0.548 |
| AST[median (q1-q3), U/L] | 95.9(55.28-167.53) | 71.6(49.8-151.4) | 0.484 |
| ALT [median (q1-q3), U/L] | 140.85(61.55-232.10) | 123.00(43.00-180.50) | 0.217 |
| TBil[median (q1-q3), umol/L] | 203.10(93.43-373.20) | 227.00(87.30-317.40) | 0.687 |
| <34.2 | 6 (18.75) | 1 (6.25) | 0.470* |
| ≥34.2 | 26 (81.25) | 15 (93.75) | |
Data are presented as standard deviation (mean ± SD), or as median (interquartile range), or as number (percentage). OS: Open Surgery; LS: Laparoscopic Surgery; BMI, Body Mass Index; ASA, American Society of Anesthesiologists; PTBD, Percutaneous Transhepatic Biliary Drainage; CA-199, Carbohydrate antigen 19-9; CEA, Carcinoembryonic antigen; CA125, Carcinoembryonic antigen 125; ALT, Alanine aminotranferease; AST, Aspartate aminotransferase; TBil, Total Bilirubin. *Fisher exact test.
Pathological findings in the OS and LS groups.
| Variables | OS group (n = 32) | LS group (n = 16) |
|
|---|---|---|---|
| Bismuth type, n (%) | 0.838 | ||
| IIIa | 15 (46.88) | 7 (43.75) | |
| IIIb | 17(53.13) | 9 (56.25) | |
| Tumor diameter [mean ± SD,cm] | 2.66 ± 1.04 | 2.58 ± 1.13 | 0.697 |
| Degree of differentiation, n (%) | 0.402 | ||
| Well-differentiated | 5 (15.63) | 1 (6.25) | |
| Moderately-differentiated | 12 (37.5) | 9 (56.25) | |
| Poorly-differentiated | 15 (46.88) | 6 (37.5) | |
| TNM stage, n (%) | 0.956 | ||
| I | 1 (3.12) | 1 (6.25) | |
| II | 8 (25) | 4 (25) | |
| IIIA | 6 (15.79) | 2 (12.5) | |
| IIIB | 6 (18.75) | 52(12.5) | |
| IIIC | 7 (21.88) | 4 (25) | |
| IVA | 4 (12.5) | 3 (18.75) | |
| Perineural involvement, n (%) | 11 (34.38) | 6 (37.5) | 0.831 |
| Microvascular invasion, n (%) | 1 (3.12) | 1 (6.25) | 0.798* |
| Lymph node involvement, n (%) | |||
| Total number [median (q1-q3)] | 6 (5 - 7) | 7 (5 - 8) | 0.146 |
| Positive rate | 7 (21.88) | 7 (43.75) | 0.217* |
Data are presented as standard deviation (mean ± SD) or as median (interquartile range). * Fisher’s exact test. OS, open surgery; LS, laparoscopic surgery.
Intraoperative data and surgical effectiveness in the OS and LS groups.
| Variables | OS group (n = 32) | LS group (n = 16) |
|
|---|---|---|---|
| Operative time (mean ± SD, min) | 407.97 ± 76.06 | 489.69 ± 79.17 | 0.001 |
| Blood loss [median (q1-q3), mL] | 600(400-800) | 300(200-400) | 0.012 |
| Intraoperative blood transfusion, n (%) | 24(75) | 8(50) | 0.083 |
| Hepatectomy | 0.838 | ||
| Left hemihepatectomy + hepatectomy, n (%) | 17 (53.12) | 13 (56.25) | |
| Right hemihepatectomy + hepatectomy, n (%) | 15 (46.88) | 6 (43.75) | |
| Resection margin, n (%) | 0.867* | ||
| R0 | 28 (87.5) | 15 (93.75) | |
| R1 | 4 (12.5) | 1 (6.25) | |
| Vascular resection and reconstruction, n (%) | 2 (6.25) | 1 (6.25) | 0.527* |
| Complications, n (%) | |||
| Clavien-Dindo grade < 3 | 25 (78.12) | 14(87.5) | 0.695* |
| Clavien-Dindo grade ≥ 3 | 7(21.88) | 2(12.5) | |
| Incision infection | 1 (3.12) | 1 (6.25) | 0.798* |
| Gastrointestinal hemorrhage | 0 (0) | 0 (0) | 1.000* |
| Intra-abdominal hemorrhage | 1(3.13) | 0 (0) | 0.721* |
| Delayed gastric emptying | 2 (6.25) | 1 (6.25) | 0.527* |
| Pleural effusion | 3 (9.38) | 1 (6.25) | 0.854* |
| Ascites | 2 (6.25) | 1 (6.25) | 0.527* |
| Pulmonary infection | 3 (9.38) | 2 (12.5) | 0.867* |
| Abdominal infection | 2 (6.25) | 1 (6.25) | 0.527* |
| Liver failure | 0 (0) | 0 (0) | 1.000* |
| Bile leakage | 0 (0) | 0 (0) | 1.000* |
| Post-operative hospital stay [median (q1-q3),day] | 14(11.25-21.25) | 11.5(10.00-17.75) | 0.254* |
| 30-day readmission rate, n (%) | 4 (12.5) | 1 (6.25) | 0.867* |
| 90-day mortality rate, n (%) | 1 (3.12) | 0 (0) | 0.721* |
| Hospitalization expenses [median (q1-q3),RMB] | 95697(80306.25-117588.33) | 105170(98160.05-119130) | 0.213 |
Data are presented as standard deviation (mean ± SD) or as number (percentage). * Fisher’s exact test. OS, open surgery; LS, laparoscopic surgery.
Long-term outcomes in the OS and LS groups.
| Variables | OS group (n = 32) | LS group (n = 16) |
|
|---|---|---|---|
| Followed-up duration [median (q1-q3), months] | 13.5 (9.25_21.75) | 12 (8.25 – 15.50) | 0.303 |
| Total recurrence rate, n (%) | 10(31.25) | 4 (25) | 0.911* |
| Local recurrence | 5 (15.63) | 3 (18.75) | 0.999* |
| Distant metastasis | 5 (15.63) | 1(6.25) | 0.643* |
| Total mortality rate, n (%) | 7 (21.88) | 3 (18.75) | 0.999* |
#Wilcoxon signed rank test. *Chi-square test with continuous correction. OS, open surgery; LS, laparoscopic surgery.
Figure 4Comparisons of overall survival and disease-free survival using Kaplan-Meier curves. (A) the 1- year survival rates were 92.28% in the OS group and 91.67% in the LS group, and 2-year survival rates was 35.16% in the OS group and 34.37% in the LS group (P=0.536). (B) The 1-year disease-free survival (DFS) rate was 82.16% in the OS group and 82.96% in the LS group, and the 2-year DFS rate was 38.64% in the OS group and 46.09% in the LS group (P=0.911).